Pfizer · 1 month ago
Principal Scientist, Analytical Project Lead - Peptides
Pfizer is a leading pharmaceutical company dedicated to delivering breakthroughs that change patients' lives. The Principal Scientist will lead analytical strategies for synthetic peptide drug substance development, ensuring quality and regulatory compliance while mentoring team members.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Developing analytical strategies in support of synthetic peptide drug substance during all development phases, including supporting manufacturing process development, assessment of starting materials, developing, validating and transferring analytical methods, designing stability studies to understand degradation mechanisms and for shelf-life assignments, developing impurity control strategies, and authoring associated regulatory documentation
Perform lab work and will plan, direct, and review the lab work of other scientists in a matrix environment
Collaboration with internal colleagues and external partners to identify appropriate analytical approaches, including use of computational predictive tools, modeling software and data visualization tools where appropriate
Critically review and interpret scientific data to derive clear conclusions and provide direction for future work and will communicate results and conclusions through various media including presentations and technical reports
Evaluate new approaches, instrumentation or analytical technologies and mentor other scientists
Author relevant sections of the quality modules of regulatory submissions
Qualification
Required
Ph.D in Analytical Chemistry or related field, with 4+ years of R&D experience or MSc with 9+ years' of R&D experience
Demonstrated oral and written communication skills, including visualization of data, presentations and authoring technical articles
Demonstrated ability to meet timelines and interact with multi-disciplinary teams
Demonstrated ability to learn new techniques and solve complex analytical problems
Attention to detail, strong organizational skills, and effective interpersonal and communication skills are required
Proficient with a wide variety of software and information systems
Preferred
Experience with analytical aspects of synthetic peptide modalities, including hands on experience with advanced chromatographic analysis and method development along with fundamental understanding and working knowledge of various analytical techniques key to synthetic peptide drug substance development including MS, NMR, AAA, ICP-MS, GC, as well as higher order structure techniques (CD, MALS, etc.)
Understanding of impurity control strategies for synthetic peptides, including highlighting key risk factors associated with the synthetic scheme and purification processes
Knowledge and experience with formal structural elucidation of peptide related impurities
Demonstrated experience authoring and defending analytical strategies in regulatory submissions
Demonstrated breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact
Sound knowledge of stage appropriate method development and related regulatory considerations
Benefits
Participation in Pfizer’s Global Performance Plan with a bonus target of 15.0% of the base salary
Participate in our share based long term incentive program
401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution
Paid vacation
Holiday and personal days
Paid caregiver/parental and medical leave
Health benefits to include medical, prescription drug, dental and vision coverage
Company
Pfizer
Pfizer is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines.
Funding
Current Stage
Public CompanyTotal Funding
$38BKey Investors
Starboard Value
2025-11-21Post Ipo Debt· $6B
2024-10-07Post Ipo Equity· $1B
2023-05-16Post Ipo Debt· $31B
Recent News
2026-01-16
Digital Journal
2026-01-16
Company data provided by crunchbase